Compare ATAT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATAT | FOLD |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 3.1B |
| IPO Year | 2022 | 2007 |
| Metric | ATAT | FOLD |
|---|---|---|
| Price | $42.40 | $14.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $46.16 | $29.79 |
| AVG Volume (30 Days) | 1.5M | ★ 14.8M |
| Earning Date | 11-25-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 25.36 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $1,276,315,178.00 | $598,704,000.00 |
| Revenue This Year | $37.61 | $21.49 |
| Revenue Next Year | $23.33 | $18.25 |
| P/E Ratio | $28.26 | ★ N/A |
| Revenue Growth | ★ 36.24 | 21.28 |
| 52 Week Low | $21.50 | $5.51 |
| 52 Week High | $43.17 | $14.36 |
| Indicator | ATAT | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 91.17 |
| Support Level | $40.40 | $10.64 |
| Resistance Level | $43.17 | $14.36 |
| Average True Range (ATR) | 1.32 | 0.34 |
| MACD | -0.05 | 0.39 |
| Stochastic Oscillator | 71.24 | 97.25 |
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.